Continued use of tamoxifen may make your periods less regular, lighter or stop altogether. When you start taking tamoxifen it may stimulate the release of an egg from the ovary (ovulation) and could make you more fertile. It’s possible to become pregnant while taking tamoxifen even if your periods have become irregular or stopped. Taking tamoxifen while pregnant may be harmful to a developing baby. Ask your treatment team or pharmacist before taking any herbal products or supplements. If this is the case, your treatment team may suggest an alternative. The two classes of drugs that you will see bodybuilders and performance athletes who use anabolic steroids (AAS) continually talk about are SERMs and Aromatase Inhibitors (AIs). The great thing about Nolvadex is that it can do this WITHOUT crashing your estrogen levels. As steroid-using bodybuilders, our greatest interest in using Nolvadex on cycle is to take advantage of its targeting of breast cells to prevent and reverse the symptoms of gynecomastia. Unlike aromatase inhibitors, which work to lower overall estrogen levels, SERMs are selective. But before you become concerned about estrogen activity, this particular form is considered positive because there’s a benefit for cholesterol when some estrogenic activity in the liver occurs. While this works very well in the breast area, Nolvadex can be an estrogen agonist in other body parts, which means it can act as estrogen, primarily affecting the liver. Nolvadex is known for its excellent ability to stimulate testosterone levels while blocking the effect of estrogen, enabling greater amounts of luteinizing hormone (LH) released by the pituitary gland. Traditional aromatase inhibitor drugs often used for gynecomastia in male bodybuilders come with significant risks to your cholesterol and in crushing your estrogen levels. So those steroids that do aromatize need to have these effects addressed; otherwise, you get out-of-control estrogen conversion, rising estrogen levels, and lower testosterone levels. In contrast, SERMs like Nolvadex, Clomid, and Toremifene are only effective at controlling gyno because these drugs were developed to target breast tissue estrogen receptors. Both are valued and used for their beneficial effects in reducing or preventing estrogen-related side effects of steroids and to assist with restoring testosterone function as part of post-cycle therapy. A clinical strategy was described that led to the creation of SERMs as a group of multifunctional medicines aimed at the treatment or prevention of many conditions in postmenopausal women, e.g. osteoporosis and breast cancer. As of 2004update, tamoxifen was the world's largest selling hormonal drug for the treatment of breast cancer. Other antiestrogens, such as ethamoxytriphetol (MER-25) and clomifene (MRL-41), were assessed for treatment of breast cancer and found to be effective before tamoxifen, but were plagued with toxicity issues. Additionally, it is the most common hormone treatment for male breast cancer. Tamoxifen, sold under the brand name Nolvadex among others, is a selective estrogen receptor modulator used to prevent breast cancer in women and men. While some studies suggest that Tamoxifen can improve sperm count and motility by increasing testosterone levels, other research indicates potential negative effects on semen quality. By acting as an estrogen antagonist in some tissues, Tamoxifen can lead to increased levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn can boost testosterone production. Several clinical trials have investigated the efficacy of Tamoxifen in raising testosterone levels in men. One of the primary benefits of Tamoxifen in raising testosterone levels is the restoration of energy and vitality. It was not until 1998 that the meta-analysis of the Oxford-based Early Breast Cancer Trialists' Collaborative Group showed definitively that tamoxifen was effective for early breast cancer. Walpole also may have helped to convince the company to market tamoxifen for late stage breast cancer in 1973. The first clinical study of tamoxifen took place at the Christie Hospital in 1971, and showed a convincing effect in advanced breast cancer, but nevertheless ICI's development programme came close to termination when it was reviewed in 1972. Furthermore, tamoxifen treatment alone has been shown to have anti-angiogenetic effects in animal models of cancer which appear to be, at least in part, independent of tamoxifen's ER antagonist properties. This unusual profile of DRI activity has made tamoxifen of potential interest as a starting point for structural modification to develop novel pharmaceutical drugs for treatment of stimulant use disorder. However, it has progonadotropic effects in premenopausal women and increases estrogen levels by 6-fold in them. In contrast, when AIB-1 expression is higher than PAX2, tamoxifen/ER complex upregulates the expression of ERBB2 resulting in stimulation of breast cancer growth.
